Joel Greenblatt

Joel Greenblatt

Last Update: 05-15-2017

Number of Stocks: 975
Number of New Stocks: 268

Total Value: $7,876 Mil
Q/Q Turnover: 33%

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

Joel Greenblatt Watch

  • Joel Greenblatt Raises Holdings of CVS Health, Priceline, HP

    Joel Greenblatt (Trades, Portfolio) is known for the invention of Magic Formula Investing and founder of the New York Securities Auction Corp. (NYSAC). During the fourth quarter the guru bought shares of the following stocks:


    He boosted his position of Ingersoll-Rand PLC (IR) by 7,388.42% with an impact of 0.71% on the portfolio.

      


  • Gotham Index Plus: A Better Way to Invest?

    In an article I wrote for our subscribers over the weekend, I noted that toward the end of a bull cycle, the market still goes up but many, ultimately giving way to most, stocks do not. That conundrum is explained because it is mostly the large-cap names always in the news (which have already moved up significantly) that see the greatest inflows. This is the phase in which previously skeptical or on-the-sidelines investors see nothing but great reports, earnings beats and, of course, Wall Street projections that say not only is the bull not fading, the next bull cycle is just getting started. This is when the somnambulists finally buy so they do not feel like they have missed the entire party.


    Some people have short memories. Not everyone was investing during the ferocious decline at the turn of the millennium. No one investing today, however, likely escaped the 50% decline in the S&P 500 index between October 2007 and March 2009, when index funds were anathema to investors who saw everything they had made in the previous bull evaporate.

      


  • Is Williams-Sonoma a Better Bargain Than Ever?

    (Published by Nicholas McCullum on March 19)


    The retail sector has been under pressure for some time now.

      


  • Multiple Vitamin Shoppe Insiders Reduce Holdings

    Several Vitamin Shoppe (NYSE:VSI) insiders have reduced their positions thus far in March.


    Director Richard Markee sold 100,000 shares of Vitamin Shoppe for $22.24 per share on March 3. He now owns 60,990 shares of the company.

      


  • Columbia Wanger Buys LCI Industries, Nasdaq

    Columbia Wanger (Trades, Portfolio) manages a portfolio composed of 197 stocks with a total value of $7.123 billion. During the fourth quarter the guru bought shares in the following stocks:


    The guru purchased 667,687 shares of LCI Industries Inc. (LCII), establishing a new position. The trade had an impact of 1.01% on the portfolio.

      


  • Testing Graham’s Net Current Asset Value Strategy, Part 2

    In the first part of this series testing Benjamin Graham’s net current asset value (NCAV) strategy, we reviewed different studies that confirmed the effectiveness of this strategy in regard to outperformance.


    But what about reality? No one can purchase every single net-net stock. You have to make choices, commissions must be paid. The spread between bid and ask prices can make it difficult or expensive to purchase these stocks.

      


  • Joel Greenblatt Cuts Hewlett Packard, Walt Disney, Oracle

    Joel Greenblatt (Trades, Portfolio) is known for the invention of Magic Formula Investing, and founder of the New York Securities Auction Corporation (NYSAC). Greenblatt is founder and managing partner of Gotham Asset Management LLC. During the fourth quarter the guru sold shares in the following stocks:


    The investor reduced his shares in Hewlett Packard Enterprise Co. (HPE) by 68.53% with an impact of -0.84% on the portfolio.

      


  • Stocks Steven Cohen Continues to Buy

    Steven Cohen (Trades, Portfolio), a billionaire hedge fund investor, is the founder of SAC Capital Advisors, a Stamford, Connecticut-based hedge fund that he continues to manage. He manages a portfolio composed of 668 stocks with a total value of $14.303 billion. In both the fourth and third quarters of 2016 the guru bought shares in the following stocks:


    LHC Group Inc. (LHCG)

      


  • Testing Graham’s Net Current Asset Value Strategy, Part 1

    There have been various studies analyzing the performance of Benjamin Graham’s strategy of purchasing stocks trading below net current asset value (NCAV). These stocks are also called net-nets. Graham developed and tested this criterion in the early 1930s and first described his net current asset value rule for stock selection in the 1934 edition of ”Security Analysis.”


    The common definition of net current asset value is:

      


  • A Good Long Idea in the Past, Most Valuable in the Future

    Philip Morris International Inc. (NYSE:PM), the largest publicly traded manufacturer and marketer of tobacco products, sells cigarettes all over the world.


    Intangible assets

      


  • AbbVie Regimen Recommended for HCV Infection

    AbbVie Inc. (NYSE:ABBV) communicated through the PRNewswire Monday that it received a positive feedback from the European Committee for Medicinal Products for Human Use (CHMP) about the possibility of using VIEKIRAX plus EXVIERA in a combined therapy of eight weeks to treat chronically genotype 1b HCV-infected adult patients.


    These patients are naïve to any kind of HCV treatment, and their liver shows some scar tissue forms from minimal to moderate. Therefore, they are noncirrhotic yet.

      


  • Eldorado Gold Reports 2016 Results

    Eldorado Gold Corp. (NYSE:EGO) released its fourth-quarter and full-year 2016 results on Feb. 23.


    Eldorado closed the quarter with a net loss of five cents, a 66.7% decrease on a year-over-year basis, and missed analysts’ expectations on EPS by seven cents, generating a negative surprise of 350%.

      


  • Abbott Laboratories Declares Quarterly Dividend

    Abbott Laboratories (NYSE:ABT) announced a regular quarterly dividend of 26.5 cents per share on Feb. 17.


    The dividend will be paid on May 15 to shareholders of record as of April 14.

      


  • Risk Reward With Urban Outfitters

    There have been 10 years of ups and downs in Urban Outfitters’ (NASDAQ:URBN) stock price while its financials continued to rise.


    Revenue increased 181% from $1.2 billion to over $3.5 billion in the last decade while net income almost doubled, going from $116 million to $227 million. This coincided with a 51 million share buyback, boosting the EPS by 175%. All in all, it’s been an amazing run.

      


  • 7 Stocks That Are Beating the Market

    According to GuruFocus' All-in-One Guru Screener, the following are some of the stocks that have outperformed the Standard & Poor's 500 Index over the last 12 months and were bought by gurus during the last quarter.


    ONEOK Partners LP (NYSE:OKS) with a market cap of $14.88 billion has outperformed the S&P500 Index by 88.5% over the last 12 months.

      


  • AbbVie Declares Quarterly Dividend

    AbbVie Inc. (NYSE:ABBV) annouced a quarterly dividend of 64 cents per share on Feb. 16.


    The dividend will be paid on May 15 to shareholders of record as of April 13.

      


  • 8 of the Worst Stocks in Gurus' Portfolios

    While gurus hold positions in these companies, the stock price and returns continue to fall. These are the worst-performing stocks over the last three months with a long-term presence in more than four gurus’ portfolios.


    Vera Bradley Inc. (NASDAQ:VRA) had a negative performance of 27.3% over the last six months. Despite this, four mutual funds are holding the stock with a total weight of 4.56% on their portfolios.

      


  • EAT DIN(ner) With These 2 Restaurant Stocks

    As we are reaching new highs on the Dow and S&P 500, some companies still cannot catch the tide. Two in particular are Brinker International Inc. (NYSE:EAT), which is down 17% since the election, and DineEquity Inc. (NYSE:DIN), which is off over 21% in the same time.


    For some background, Brinker International is the owner Chili’s and Maggiano’s restaurants with over 1,600 locations. DineEquity owns Applebee's and the International House of Pancakes and has over 3,700 locations across the brand. Make no mistake about it, both are brands. That is why the recent drop in the two companies’ stock price is more of a buying opportunity than a value trap.

      


  • 10 Questions With Value Investor T. Aaron Brown

    1. How and why did you get started investing? What is your background?


    I have a scenic tour background. Many turns. I was a math teacher and then a youth counselor before I started working in government. I have held agent positions with both state and federal departments. I started investing a few years out of college with a series of trial by error. My primary editor is Seeking Alpha. I like the community as it provides a lot of feedback.

      


  • AbbVie's Hepatitic C Treatment Under Accelerated Review by EMA

     AbbVie Inc. (NYSE:ABBV) announced Tuesday through the PR Newswire that the European Medicines Agency has validated its marketing authorization application. The company's application seeks permission to rapidly bring its “investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P)” to the market.


    The regimen, which is “now under accelerated assessment by EMA,” is used as treatment for patients affected with genotypes 1–6 of the hepatitis C virus.

      


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}